These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Thermostability of a trivalent, capsomere-based vaccine for human papillomavirus infection. Dong M; Meinerz NM; Walker KD; Garcea RL; Randolph TW Eur J Pharm Biopharm; 2021 Nov; 168():131-138. PubMed ID: 34438020 [TBL] [Abstract][Full Text] [Related]
4. Atomic-Layer Deposition Processes Applied to Phage λ and a Phage-like Particle Platform Yield Thermostable, Single-Shot Vaccines. Witeof AE; McClary WD; Rea LT; Yang Q; Davis MM; Funke HH; Catalano CE; Randolph TW J Pharm Sci; 2022 May; 111(5):1354-1362. PubMed ID: 35081408 [TBL] [Abstract][Full Text] [Related]
5. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663 [TBL] [Abstract][Full Text] [Related]
6. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles. Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935 [TBL] [Abstract][Full Text] [Related]
7. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. Park JS; Oh YK; Kang MJ; Kim CK J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729 [TBL] [Abstract][Full Text] [Related]
9. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912 [TBL] [Abstract][Full Text] [Related]
10. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886 [TBL] [Abstract][Full Text] [Related]
11. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603 [TBL] [Abstract][Full Text] [Related]
12. Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Hassett KJ; Meinerz NM; Semmelmann F; Cousins MC; Garcea RL; Randolph TW Eur J Pharm Biopharm; 2015 Aug; 94():220-8. PubMed ID: 25998700 [TBL] [Abstract][Full Text] [Related]
13. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002 [TBL] [Abstract][Full Text] [Related]
14. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus. Saboo S; Tumban E; Peabody J; Wafula D; Peabody DS; Chackerian B; Muttil P Mol Pharm; 2016 May; 13(5):1646-55. PubMed ID: 27019231 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial. Li J; Shi LW; Yu BW; Huang LR; Zhou LY; Shi L; Jiang ZW; Xia JL; Wang XY; Li RC; Yuan L; Li YP; Li CG Vaccine; 2023 May; 41(19):3141-3149. PubMed ID: 37061370 [TBL] [Abstract][Full Text] [Related]
16. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490 [TBL] [Abstract][Full Text] [Related]
18. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932 [TBL] [Abstract][Full Text] [Related]
19. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. Godi A; Bissett SL; Miller E; Beddows S PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976 [TBL] [Abstract][Full Text] [Related]
20. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation. Park MH; You JW; Kim HJ; Kim HJ J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]